Symrise AG (OTCMKTS:SYIEY – Get Rating) – Research analysts at Jefferies Financial Group lifted their FY2024 earnings per share (EPS) estimates for Symrise in a note issued to investors on Wednesday, September 14th. Jefferies Financial Group analyst C. Counihan now expects that the company will post earnings per share of $1.16 for the year, up from their prior forecast of $1.12. The consensus estimate for Symrise's current full-year earnings is $0.82 per share. Jefferies Financial Group also issued estimates for Symrise's FY2025 earnings at $1.28 EPS.
Get Symrise alerts:Separately, Berenberg Bank reduced their price objective on shares of Symrise from €119.00 ($121.43) to €114.00 ($116.33) and set a "hold" rating on the stock in a research note on Tuesday, July 19th. Four investment analysts have rated the stock with a hold rating and one has given a buy rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Hold" and an average price target of $117.00.
Symrise Stock Down 1.5 %
Shares of SYIEY stock opened at $24.86 on Thursday. The business's 50 day simple moving average is $27.28 and its 200 day simple moving average is $27.84. The company has a current ratio of 2.04, a quick ratio of 1.17 and a debt-to-equity ratio of 0.41. Symrise has a one year low of $24.63 and a one year high of $37.21.Symrise Company Profile
(Get Rating)
Symrise AG supplies fragrances, flavorings, cosmetic active ingredients and raw materials, and functional ingredients. It operates through two segments, Taste, Nutrition & Health, and Scent & Care. The Taste, Nutrition & Health segment provides functional ingredients and flavor solutions used in the production of food and beverages; savory flavors; natural and sustainable ingredients for food and beverage manufacturers, baby food, and dietary supplements; product solutions and services for pet food manufacturers; sustainable ingredients and services for aqua feed manufacturers to develop solutions for fish and shrimp farms; and probiotics for food supplements and functional foods.
See Also
- Get a free copy of the StockNews.com research report on Symrise (SYIEY)
- Is There a Cure for What is Ailing Teladoc Stock?
- No One Told These 3 Stocks It's a Down Week
- Why Medical Products Maker Repligen May Be A Potential Buy
- At 10%, Is Arbor Realty Trust Dividend Worth It?
- Investors Should Tune Into RF Industries
Receive News & Ratings for Symrise Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Symrise and related companies with MarketBeat.com's FREE daily email newsletter.